Key result
Primary malignant fibrous histiocytoma of the bladder runs a very aggressive course, with overall 1- and 2-year disease-specific survival rates of only 47.8% and 31.9%.
Why the study?
Does radical oncosurgery improve disease-specific survival in patients with primary malignant fibrous histiocytoma of the urinary bladder?
Does radical oncosurgery improve disease-specific survival in patients with primary malignant fibrous histiocytoma of the urinary bladder?
Answers are grounded in this paper and cite their sources.
Primary malignant fibrous histiocytoma of the bladder has a dismal prognosis with 1- and 2-year disease-specific survival rates of only 47.8% and 31.9%, regardless of therapeutic options.
Disease-specific survival (DSS) rates were evaluated in 20 patients with primary malignant fibrous histiocytoma (MFH) of the bladder. The most common pathologic finding was the pleomorphic subtype of MFH (55%) with a mean tumor size of 6.8 cm. 10 patients underwent surgery without and 6 patients with adjuvant therapy. Local and systemic rates of progression were 30 and 60% after surgery only compared with 16.7 and 50% after surgery with adjuvant therapy. Although none of the patients showed metastatic dissemination at the time of diagnosis, overall 1- and 2-year DSS rates of only 47.8 and 31.9% were observed. Hence, after the onset of clinical symptoms, the disease runs a very aggressive course regardless of the therapeutic options employed. Although distant dissemination seems to be rare at the time of diagnosis, the prognostic outcome is dismal. The rarity and inconsistency of the currently available case reports on MFH of the bladder hampers the development of therapeutic guidelines. Advanced studies enrolling a larger number of patients with appropriate clinical and pathological data are needed to compare the beneficial effects of various treatment options.
No takes yet. Share an insight, caveat, or question.
Gunia et al. (2011) conducted a review in Primary malignant fibrous histiocytoma (MFH) of the bladder (n=20). Surgery with adjuvant therapy vs. Surgery only was evaluated on Disease-specific survival (DSS) rates. Primary malignant fibrous histiocytoma of the bladder runs a very aggressive course, with overall 1- and 2-year disease-specific survival rates of only 47.8% and 31.9%.
Synapse has enriched 10 related papers. Consider them for comparative context: